Nelson Advisors: 10 Key Issues Killing European HealthTech, MedTech and Health AI Deals in the Current Market


A market that looks healthy from a distance
European healthcare dealmaking in 2026 is growing in value and shrinking in number. Mergermarket counted 522 European healthcare deals worth €39.9bn in the first half of the year, a 56% rise in value on 50 fewer transactions than the same period of 2025 (Mergermarket). Venture funding has the same shape.
European healthtech raised about €1.6bn of equity in Q3 2026, up roughly 20% year on year, but across 89 rounds rather than 110 (Early Early Stage).
The headline numbers hide a split market. A small group of scaled, profitable or category-defining assets attracts fierce competition and premium prices. Everything else, which is most of the lower and mid market, faces longer processes, harder diligence and buyers who are happy to walk away.
Time is the clearest symptom. Advisers quoted by Mergermarket describe sale processes that once took a few months now running 12 to 14 months. A process that long rarely dies from one dramatic event. It dies because a certificate lapses, a quarter is missed, a lead investor loses patience or a buyer's investment committee changes its mind.
Our article below sets out the ten issues that most often kill European healthtech, medtech and health AI deals today. None is new on its own. What is new is how many of them now turn up in the same transaction. Each section ends with what a seller can do about it, because most of these deal killers are visible, and fixable, long before a buyer finds them.
1. The valuation gap that will not close
The most common deal killer is still the simplest: seller and buyer disagree on price, and neither moves. Many European healthtech companies raised their last priced round in 2021 or early 2022. That round set a valuation, a preference stack and a set of investor expectations that today's buyers do not recognise.
Buyers now price on current revenue quality, margin and cash generation. Sellers price on the last round plus the capital spent since. The two numbers can sit a long way apart before a single diligence question has been asked.
The gap has narrowed at the top of the market. Bain's 2026 medtech M&A report describes a strong rebound in deal value as valuations kept softening, and warns that still softer valuations would intensify competition for quality assets (Bain). That is exactly the problem for the mid market. Lower prices have pulled buyers towards the best assets, not towards the average one.
The gap is also structural, not only emotional. A board that accepts a price below the preference stack leaves founders and employees with little or nothing. Management then has no reason to support the sale, and buyers will not acquire a company whose team does not want the deal.
What sellers can do. Anchor expectations on recent comparable transactions, not on funding rounds. Agree among shareholders, before going to market, what price range is acceptable and how proceeds would be shared at each level. Use structure to bridge what remains: deferred consideration, earn-outs tied to verifiable milestones, or rollover equity where the buyer is a sponsor.
2. MDR and IVDR: reform promised, nothing settled
The second killer is regulatory limbo. The European Commission proposed a major simplification of the Medical Devices Regulation and the In Vitro Diagnostic Regulation on 16 December 2025. Eleven months later it is still a proposal.
As of October 2026, the Parliament's lead committee had not voted on its draft report, and the only forward date was an indicative first-reading plenary on 14 December. The Council's June progress report said more work was needed before member states could agree a position (Deemed Consulting). Trilogue cannot start until both sides have one. Until a final text is published, the existing regulations apply in full.
For dealmaking this is the worst of both worlds. Buyers must diligence a target against today's rules, including the transition deadlines for legacy devices that fall at the end of 2027 and 2028. They must also price a future regime that could change certificate validity, notified body oversight and the classification of medical software.
In practice, three findings stop medtech deals:
Legacy products still on old directive certificates with no credible MDR timetable.
Technical files and clinical evaluations that would not survive a notified body review.
Revenue concentrated in products whose certification depends on a single overstretched notified body.
A buyer who finds any of these late in a process will reprice or withdraw. Warranty and indemnity insurers often exclude known regulatory gaps, which pushes the risk straight back to the seller.
What sellers can do. Build a regulatory data room before launch. Show certificate status by product, the notified body timetable, open non-conformities and the cost to complete. A gap with a funded plan is a price discussion. A gap the buyer discovers is a broken deal.
3. The EU AI Act: more time, same double burden
Health AI companies got a delay in 2026, not a reprieve. EU co-legislators reached a political agreement on the Digital Omnibus on 7 May 2026. It keeps medical technologies inside the AI Act's high-risk regime. Industrial AI won an exemption; medical devices did not (MedTech Europe).
The application date for high-risk AI embedded in regulated products such as medical devices moves back 12 months to 2 August 2028 (Browne Jacobson). The industry had asked for something different: one compliance pathway, run through the MDR and IVDR. What it got was parallel obligations under both frameworks, with the MDR revision now the main hope for removing the overlap.
This matters in a transaction because a buyer is acquiring a compliance liability it cannot yet size. The harmonised standards that companies will be assessed against are not finished. Notified bodies need capacity for a second regime. Any AI-enabled device in Class IIa or above that needs notified body review is caught.
Acquirers respond in predictable ways. Strategic buyers ask whether the product can be folded into their own quality system and at what cost. Financial buyers model a compliance budget and deduct it from the price. US buyers, who see lighter-touch routes at home, sometimes conclude the European product line is not worth the trouble.
The delay also creates a timing trap. A sponsor buying in 2026 or 2027 will own the asset on the August 2028 deadline, so the cost lands inside its hold period.
What sellers can do. Produce a written classification for every AI feature under both the MDR and the AI Act. Add a gap analysis and a costed plan to August 2028. Buyers do not expect full compliance today. They do expect management to know the distance left.
4. Reimbursement that stops at the border
A product that is paid for in one European country is not paid for in the next. That single fact undermines more healthtech growth plans, and more acquisition models, than any technology risk.
Europe has built national fast-track routes, not a European one. Germany's DiGA pathway reimburses lower-risk digital health applications through statutory insurers. France's PECAN scheme offers a one-year, non-renewable coverage window for digital medical devices while evidence is gathered. England relies on NICE assessment and NHS procurement (Nelson Advisors). Each has its own evidence standard, price mechanism and timetable.
The rules also move. Germany's 2026 reforms tie at least 20% of a DiGA's price to measured patient outcomes (Nelson Advisors). A provisional price set by the manufacturer in year one is routinely negotiated down afterwards.
Buyers have learned to read this carefully. They discount three things heavily:
Revenue earned under provisional or time-limited listings.
Forecasts that assume a second or third country will reimburse on the first country's evidence.
Business plans in which the payer has not yet been identified.
The result is a familiar deadlock. The seller's valuation rests on multi-country expansion. The buyer will pay only for the one market where money already flows.
What sellers can do. Separate permanent from provisional reimbursement in the numbers. Show the health economic evidence already accepted by a payer, and what each additional market would require in studies, time and cash. Where reimbursement is not realistic, show a direct route to provider or employer budgets with signed contracts behind it.
5. Slow procurement and revenue that is not what it seems
Buyers pay for predictable revenue, and European health systems make revenue hard to predict. One adviser told Mergermarket that pipelines are full but "the problem is visibility for the buyers." That sentence describes most failed healthtech processes of the past year.
Selling to hospitals and public health systems is slow. Tenders run for many months, budgets are annual, and a change of government or regional leadership can reset a decision. A company can do everything right commercially and still miss its forecast by two quarters.
In a 12-month sale process, two missed quarters are fatal. The buyer's model was built on the forecast in the information memorandum. When actual numbers arrive below it, trust goes before price does.
Diligence then exposes the quality of what has been booked. The same problems appear again and again:
Pilots and grant-funded projects reported as recurring revenue.
Contracts with break clauses, short terms or renewal subject to fresh tender.
One or two customers providing most of the revenue.
Implementation and services income presented alongside software subscriptions.
Long gaps between contract signature and go-live, so booked revenue is not yet billed.
None of these is unusual in healthcare. What kills deals is the difference between how the seller described the revenue and what the contracts say.
There is a sector-specific twist. Public buyers can require consent to a change of control, and some will use the moment to renegotiate. Acquirers know this and ask for consents before signing, which hands customers a veto over the deal.
What sellers can do. Classify every revenue line honestly before launch: contracted recurring, re-tendered, pilot, services. Forecast conservatively and beat it during the process. Review change-of-control clauses early and open conversations with key customers before a buyer asks.

6. Health AI that does not survive diligence
AI is the reason many buyers open a data room, and the reason many of them close it. Capital is flowing to health AI at scale: Sweden's Tandem Health raised an €86.5m Series B in 2026 led by the Scaleup Europe Fund (Retail Banker International). That appetite has made every seller describe itself as an AI company, and made every buyer sceptical.
Technical and clinical diligence on AI assets is now far deeper than it was two years ago. Four questions decide most outcomes.
Does the company own the right to use its training data? Models trained on patient data under research agreements, hospital partnerships or vague consent terms may not be usable commercially. If the data rights fail, the model's value fails with them.
Is there clinical evidence, or only technical performance? Accuracy on a retrospective dataset is not proof of benefit in practice. Buyers want prospective studies, real-world performance monitoring and regulatory clearance for the claims being made.
What is proprietary? A product that wraps a third-party foundation model has limited defensibility and a cost base it does not control. Inference costs that scale with usage can turn an apparent software margin into a services margin.
Could AI replace the business itself? Advisers now flag AI disruption as a risk to target companies, not only an opportunity (Mergermarket). Single-feature tools, such as stand-alone transcription or coding assistants, face the fastest commoditisation.
The deals that fail here usually fail on the first question. Data provenance is rarely documented well, and it cannot be repaired during a process.
What sellers can do. Map every dataset to the contract or consent that permits its use. Document model versions, validation results and post-market monitoring. Be precise about what is built in-house and what is licensed. Describe the product as what it is; over claiming on AI is found quickly and costs credibility on everything else.
7. Data protection, cyber security and the EHDS clock
Health data is the asset buyers want and the liability they fear. Under GDPR it is special category data, so the consequences of a weak legal basis, a poorly drafted processing agreement or an unreported breach are larger than in almost any other software sector.
Data and security diligence used to be a workstream. It is now a gate. Buyers commission penetration tests, review incident logs and trace data flows across sub-processors and cloud regions. A serious unremediated vulnerability, or a breach the seller did not disclose, ends a process on the spot.
A new deadline sharpens this. The European Health Data Space Regulation entered into force in March 2025 and reaches its general application date on 26 March 2027 (McCann FitzGerald). The Commission's key implementing acts are due by the same date. From 2029, new EHR systems covering the first data categories will need to support the European exchange format, keep access logs and carry CE marking (eCorpIT).
For EHR, interoperability and data platform vendors, that is a product roadmap cost a buyer must fund. Readiness on the customer side is patchy too. A Black Book study of 881 healthcare leaders in 14 countries found that awareness of the EHDS is widespread but dedicated 2026 to 2028 implementation budgets are inconsistent (Black Book Research). The same study found providers asking which vendors will be contractually accountable.
That last point reaches straight into deal terms. If customers push EHDS obligations into vendor contracts, the acquirer inherits them.
There is an opportunity here as well as a risk. Vendors that are demonstrably ready will win replacement business from those that are not, and buyers will pay for that position.
What sellers can do. Hold current security certifications and a recent independent penetration test. Keep a complete record of processing, sub-processors and data transfers. Prepare an EHDS impact assessment with a costed roadmap, and disclose past incidents with the remediation evidence.
8. Capital concentration and the growth funding gap
European healthtech funding is rising in total and falling for the typical company. In Q3 2026, Neko Health's $700m Series C accounted for about 38% of all equity raised in the sector. Strip it out and the remaining 88 rounds raised roughly €1.0bn, an average of about €11.2m each (Early Early Stage). The number of equity rounds fell 19% year on year.
The year started weaker still. Galen Growth recorded $1.2bn of European digital health venture funding across 67 deals in Q1 2026, with funding down 44% and deal count down 46% on a year earlier. Europe took 17% of global venture capital in the sector against North America's 76% (Galen Growth).
This affects M&A in three ways.
First, it creates forced sellers. A company that cannot raise its Series B or C turns to a sale with nine months of cash or less. Buyers can read a balance sheet. They slow down, the price falls as the runway shortens, and the process ends in a distressed sale or no sale.
Second, it removes the alternative. A seller's best negotiating tool is a credible ability to walk away and raise capital instead. Without a term sheet in hand, there is no competitive tension to hold a buyer to its first offer.
Third, it weakens the buyer universe. Venture-backed scale-ups that would have been natural consolidators in 2021 are conserving cash. That leaves a shorter list of large strategics and sponsors, each with more choice.
Bridge rounds make this worse when they add senior preference or punitive terms, because they widen the valuation gap described in section 1.
What sellers can do. Start a sale process with at least 12 to 18 months of runway, or secure insider funding that covers the process before launch. Run a financing track alongside the M&A track where possible. Cut burn early enough that the numbers buyers see are the improved ones.
9. Geopolitics, tariffs and dependence on the US
Macro uncertainty does not usually kill a deal directly. It gives a hesitant investment committee a reason to wait, and in a long process waiting is often enough.
2026 has supplied plenty of reasons. Mergermarket's advisers point to the Middle East conflict that began in late February, the oil price and inflation effects that followed, interest rates and the approaching French elections. Sentiment fell in the second quarter, and sponsors proved more sensitive to short-term volatility than strategic buyers (Mergermarket). Strategics accounted for 337 of the 522 first-half deals.
For medtech, US trade policy is the specific problem. The US Commerce Department opened a Section 232 national security investigation into medical devices, consumables and protective equipment on 2 September 2025. The report deadline passed at the end of May 2026. As of late October the case was still listed as open, with no determination and no device tariffs imposed under it (SPS Commerce).
An open investigation is harder to price than a known tariff. The parallel pharmaceutical action shows the range of outcomes: a 100% default duty, with 15% for EU-origin goods. A European device maker with US revenue and European manufacturing therefore carries an unquantified margin risk, and a decision could arrive with little notice.
This cuts both ways across the Atlantic. US acquirers have been the premium buyers of European medtech and health software for a decade. Some now hesitate over European regulatory cost. European sellers, in turn, find that their US growth plan, usually the core of the equity story, is the part buyers discount most.
Foreign investment screening adds time. More European governments now review acquisitions involving health data, AI or critical supply, and a non-European buyer must build that into its timetable.
What sellers can do. Quantify tariff exposure by product and manufacturing site, with scenarios. Show the mitigation options: US assembly, contract manufacturing, pricing clauses. Identify likely screening filings at the start and include European strategic buyers in the process so that it does not depend on one geography.
10. Broken cap tables, hard structures and unprepared sellers
The last killer sits inside the selling company. Many processes fail because shareholders, structure or basic preparation were never sorted out, long before any outside factor has a chance to intervene.
Shareholder misalignment. Private equity owners are under real pressure to sell. Gain's latest European report puts median holding periods at about 5.8 years, with one-third of sponsor-owned assets held for more than seven, and expects exits to fall about 10% in 2026 as sponsors keep deferring (Gain). Its data also shows new sponsor investment in science and health down 23%. Venture cap tables have the same tension: early investors want liquidity, late investors want their preference, founders want a reason to stay.
When those groups have not agreed a position, a buyer ends up negotiating with several sellers at once. Many will not.
Structure disputes. With a valuation gap to bridge, more consideration is deferred or contingent. Earn-outs tied to regulatory approvals or reimbursement decisions put the outcome in a third party's hands, and sellers resist them. Insurers carve known regulatory, data and tax issues out of warranty cover, so buyers ask for escrows and specific indemnities that funds near the end of their life cannot give.
Housekeeping failures. These are the least excusable and still common:
IP created by founders, contractors or universities that was never properly assigned.
Open-source components with licence terms nobody has reviewed.
Grant funding with clawback or change-of-control conditions.
Management accounts that do not reconcile to audited figures.
A business that depends on one founder with no retention plan.
Each one is fixable in weeks if found early. Found in confirmatory diligence, each one costs a month, and long processes do not survive many lost months.
What sellers can do. Agree the shareholder position and proceeds waterfall before launch. Commission vendor due diligence on financial, legal, regulatory and technology matters. Put management incentives in place that work at the realistic price, not the hoped-for one.
What gets deals done in this market
The deals that close in 2026 share one feature: the buyer found nothing it had not already been told. Preparation has become the main source of value a seller controls.
The ten issues fall into two groups. Regulation, reimbursement, trade policy and the funding cycle are outside any one company's control, but each can be measured, costed and disclosed. Revenue quality, data rights, security, cap table alignment and housekeeping are inside management's control and can be fixed before a process begins.
Buyers are not short of money or appetite. Deal value is up sharply, strategics are active and sponsors hold ageing portfolios they need to sell and capital they need to deploy. One adviser quoted by Mergermarket expects a quiet second half but is more positive on 2027. The regulatory calendar should be clearer by then, with an AI Act date fixed and the MDR revision further through the legislative process.
Sellers who use the next six months to close the gaps described here will meet that market in a far stronger position than those who launch first and discover the problems alongside their buyer.
Sources
Mergermarket: Strategics trump sponsors in European healthcare M&A
Early Early Stage #66: Healthtech funding, Q3 2026 and Q3 2025
Deemed Consulting: EU MDR and IVDR targeted revision, status October 2026
Browne Jacobson: AI Act application for high-risk AI medical devices delayed
Nelson Advisors: Comparative analysis of European healthcare technology frameworks
Retail Banker International: European tech investment in Q3 2026
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands




































Comments